Edition:
United States

Viveve Medical Inc (VIVE.OQ)

VIVE.OQ on NASDAQ Stock Exchange Capital Market

2.66USD
17 Jul 2018
Change (% chg)

-- (--)
Prev Close
$2.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
116,811
52-wk High
$7.42
52-wk Low
$1.60

Latest Key Developments (Source: Significant Developments)

Viveve Reports Preliminary Q2 2018 Revenue
Tuesday, 10 Jul 2018 08:28am EDT 

July 10 (Reuters) - Viveve Medical Inc ::VIVEVE REPORTS PRELIMINARY SECOND QUARTER 2018 REVENUE OF $5.5 MILLION.SEES FY 2018 REVENUE $22 MILLION TO $24 MILLION.FY2018 REVENUE VIEW $21.4 MILLION -- THOMSON REUTERS I/B/E/S.EXPANDS U.S. COMMERCIAL FOOTPRINT THROUGH PARTNERSHIP WITH AESTHETIC MANAGEMENT PARTNERS.ENTERED CAPITAL SALES PARTNERSHIP WITH AESTHETIC MANAGEMENT PARTNERS TO EXPAND IN U.S..ESTIMATED TOTAL PRODUCT REVENUE FOR THREE MONTHS ENDED JUNE 30, 2018, IS EXPECTED TO BE APPROXIMATELY $5.5 MILLION.  Full Article

Viveve Announces Settlement Of Patent Infringement Litigation With Thermi
Monday, 4 Jun 2018 08:28am EDT 

June 4 (Reuters) - Viveve Medical Inc ::VIVEVE ANNOUNCES SETTLEMENT OF PATENT INFRINGEMENT LITIGATION WITH THERMI.VIVEVE MEDICAL - REACHED SETTLEMENT TO RESOLVE PATENT LITIGATION FILED IN 2016 AGAINST THERMIGEN, THERMIAESTHETICS, AND RED ALINSOD IN U.S. COURT.VIVEVE - CO TO GET MONETARY PAYMENT, ON-GOING ROYALTY, AS WELL AS OTHER MUTUAL AGREEMENTS RELATING TO SOME INTELLECTUAL PROPERTY OWNED BY COMPANIES.  Full Article

Viveve Says FDA Signs Off On Clinical Study
Monday, 19 Mar 2018 08:28am EDT 

March 19 (Reuters) - Viveve Medical Inc ::VIVEVE ANNOUNCES FDA APPROVAL OF IDE TO CONDUCT VIVEVE II CLINICAL STUDY.VIVEVE MEDICAL INC - ‍VIVEVE II CLINICAL TRIAL EXPECTED TO BEGIN IN Q2 2018​.  Full Article

Viveve Reports Q4 Loss Per Share $0.53
Thursday, 15 Mar 2018 04:02pm EDT 

March 15 (Reuters) - Viveve Medical Inc ::VIVEVE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.53.Q4 REVENUE $5.101 MILLION VERSUS I/B/E/S VIEW $5.1 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.47 -- THOMSON REUTERS I/B/E/S.  Full Article

Viveve Announces Pricing Of Public Offering Of Shares
Thursday, 8 Feb 2018 08:01am EST 

Feb 8 (Reuters) - Viveve Medical Inc ::VIVEVE ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK.VIVEVE MEDICAL INC - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 10 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $3.00 PER SHARE.  Full Article

Viveve Announces Proposed Public Offering Of Shares Of Common Stock
Wednesday, 7 Feb 2018 04:01pm EST 

Feb 7 (Reuters) - Viveve Medical Inc ::VIVEVE ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK.VIVEVE MEDICAL - INTENDS TO USE NET PROCEEDS FROM OFFERING FOR SUPPORTING COMMERCIALIZATION OF ITS PRODUCTS, CLINICAL RESEARCH AND DEVELOPMENT.  Full Article

Viveve Announces Preliminary 2017 Fourth Quarter Results
Thursday, 4 Jan 2018 08:28am EST 

Jan 4 (Reuters) - Viveve Medical Inc ::VIVEVE ANNOUNCES PRELIMINARY 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS AND PROVIDES 2018 REVENUE GUIDANCE.SEES FY 2018 REVENUE $22 MILLION TO $24 MILLION.SEES FY 2017 REVENUE $15.3 MILLION.FY2017 REVENUE VIEW $15.5 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $23.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Viveve Medical Inc files for mixed shelf of up to $50 million
Wednesday, 8 Nov 2017 05:17pm EST 

Nov 8 (Reuters) - Viveve Medical Inc :Viveve Medical Inc files for mixed shelf of up to $50 million .  Full Article

Viveve reports Q3 loss per share $0.50
Wednesday, 8 Nov 2017 04:02pm EST 

Nov 8 (Reuters) - Viveve Medical Inc :Viveve announces third quarter 2017 financial results.Q3 loss per share $0.50.Q3 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Q3 revenue $4.1 million versus i/b/e/s view $3.7 million.  Full Article

Viveve releases preliminary Q3 2017 financial results
Wednesday, 18 Oct 2017 08:28am EDT 

Oct 18 (Reuters) - Viveve Medical Inc :Viveve releases preliminary third quarter 2017 financial results.Viveve Medical- sees Q3 revenue from sale of 60 Viveve systems, about 2,700 disposable treatment tips, ancillary consumables to be about $4.1 million​‍​.  Full Article

BRIEF-Viveve Announces Pricing Of Public Offering Of Shares

* VIVEVE ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK